Akari Therapeutics is focused on developing advanced therapies for autoimmune and inflammatory diseases, particularly through its innovative approach to treating conditions such as hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and geographic atrophy (GA). The company’s lead product candidate, Nomacopan, is a dual inhibitor of complement and leukotriene pathways, which aims to address the underlying mechanisms of these diseases. By targeting both the complement system and leukotriene signaling, Nomacopan has the potential to provide a more comprehensive treatment option for patients suffering from these challenging conditions.

In addition to Nomacopan, Akari Therapeutics is exploring other therapeutic avenues within its pipeline, emphasizing its commitment to addressing orphan diseases and unmet medical needs. The company’s research and development efforts are geared towards leveraging its proprietary technologies to create effective treatments that can significantly improve patient outcomes. Through its focus on advanced therapies, Akari Therapeutics aims to revolutionize the management of autoinflammatory diseases and enhance the quality of life for affected individuals.

United Kingdom

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Eye Diseases

Rare diseases

Akari Therapeutics

Hematopoietic stem cell transplantation thrombotic microangiopathies

Nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4.
It inhibits terminal complement activation by tightly binding to C5 and &nbsp;preventing its cleavage and activation by complement. It inhibits LTB4 &nbsp;by capturing the fatty acid within the body of the nomacopan protein. By &nbsp;preventing C5 activation of complement nomacopan can stop formation of &nbsp;the anaphylatoxin C5a which activates cells, including granulocytes and T &nbsp;and B cells, via two G protein coupled receptors, or GPCRs, and also &nbsp;prevents formation of the membrane attack complex, or MAC which &nbsp;activates cells including endothelial cells. C5a and the MAC cause and &nbsp;maintain a proinflammatory and prothrombotic state. LTB4 also activates &nbsp;cells via two separate GPCRs and can independently cause and maintain a &nbsp;proinflammatory state.
The importance of nomacopan’s dual inhibitory action is therefore &nbsp;twofold. First, it can prevent inflammatory and prothrombotic activities &nbsp;of two key pathways, and second, the pathways can be independently &nbsp;activated, for example terminal complement activation can be induced by &nbsp;IgG, IgM, carbohydrates and damage associated molecular patterns and &nbsp;LTB4 synthesis can be induced by engagement of Fc gamma receptors, &nbsp;cytokines, toll-like receptors, C5a and MAC.
<a href="https://www.akaritx.com/mode-of-action/">Source</a>

Nomacopan

Paroxysmal nocturnal hemoglobinuria

COVID-19

Nomacopan is a recombinant small protein that inhibits both terminal complement activation and leukotriene B4, or LTB4.
It inhibits terminal complement activation by tightly binding to C5 and &nbsp;preventing its cleavage and activation by complement. It inhibits LTB4 &nbsp;by capturing the fatty acid within the body of the nomacopan protein. By &nbsp;preventing C5 activation of complement nomacopan can stop formation of &nbsp;the anaphylatoxin C5a which activates cells, including granulocytes and T &nbsp;and B cells, via two G protein coupled receptors, or GPCRs, and also &nbsp;prevents formation of the membrane attack complex, or MAC which &nbsp;activates cells including endothelial cells. C5a and the MAC cause and &nbsp;maintain a proinflammatory and prothrombotic state. LTB4 also activates &nbsp;cells via two separate GPCRs and can independently cause and maintain a &nbsp;proinflammatory state.
The importance of nomacopan’s dual inhibitory action is therefore &nbsp;twofold. First, it can prevent inflammatory and prothrombotic activities &nbsp;of two key pathways, and second, the pathways can be independently &nbsp;activated, for example terminal complement activation can be induced by &nbsp;IgG, IgM, carbohydrates and damage associated molecular patterns and &nbsp;LTB4 synthesis can be induced by engagement of Fc gamma receptors, &nbsp;cytokines, toll-like receptors, C5a and MAC.
<a href="https://www.akaritx.com/mode-of-action/">Source</a>

Akari Therapeutics

Company Details